Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased wor
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 “Our nation's healthcare system ... national disgrace. Furthermore, every governmental and professional entity ... deplorable state of unorganized dysfunction shares in that ... merely serve as a device to use in ... failure(s) that have accumulated through the years leading ...
(Date:8/21/2014)... DESY scientists has observed tiny quantum vortices in cold ... journal Science that the exotic vortices arrange ... is the first time that the quantum vortices, which ... is known as superfluid helium, have been detected in ... Andrey Vilesov of the University of Southern California, one ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere ... of their Nutraceutical "TELO-20 for Dogs" with ... Telomere-lengthening supplement in the world for dogs. Telomeres ... every chromosome in the body. A wealth of ... experts in Telomere Science and Aging, including Nobel ...
(Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Issues Have Been Resolved; Remaining Issues Pertain to ... of Third-party Manufacturing Facility Company Expects to ... LEXINGTON, Mass., Dec. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... letter from the U.S. Food and Drug Administration (FDA) ...
... Allows Accurate Marketing Claims Designed with Input from,Entire ... nation,s leading livestock,cloning companies announced today a tracking ... allow food companies to identify cloned animals,when they ... program was developed through extensive cooperative discussions,over the ...
... Announcement of a Tracking Program for,Cloned Livestock, ... by International Dairy Foods Association President and CEO ... new national registry to track cloned,livestock as a ... food,products from cloned animals. However, we strongly urge ...
Cached Biology Technology:Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 2Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 3Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 4Top U.S. Cloning Companies Announce New System to Track Cloned Livestock 2Statement of International Dairy Foods Association President and CEO Connie Tipton 2
(Date:8/21/2014)... eczema and other itchy, flaky maladies in humans has ... coral reefs and the extreme environments of arctic soils ... scientific journal PLOS Pathogens considers the diversity, ... Malassezia in light of new insights gained ... , University of Hawai,i at Mānoa scientist Anthony Amend ...
(Date:8/21/2014)... Israel Deaconess Medical Center (BIDMC ) are among the ... Minds 2014," a comprehensive list compiled by ... science metrics and research performance analysis. , ... performing and publishing work that their peers recognized as ... a Thomson Reuters statement. Researchers were identified based on ...
(Date:8/21/2014)... the water window? It consists of radiations in the ... by the water in biological tissues. New theoretical findings ... within the water window. These could be the basis ... of the biological samples or to be used in ... physical mechanism needed to efficiently generate the harmonic radiationswhich ...
Breaking Biology News(10 mins):From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Water window imaging opportunity 2
... In a brief paper in the journal Bioinformatics ... Web-based program called Spliceman for predicting whether genetic mutations ... potentially leading to disease. "Spliceman takes a set ... likely these single nucleotide variants alter splicing phenotypes," write ...
... in German . The Fukushima ... not over yet, neither in Japan nor in Germany. ... working groups that are still processing scientific findings for ... the energy turnaround in Germany by conducting research into ...
... and the Department of Fish and Game have completed an ... species of greatest concern. This first-of-its-kind study prioritizes which species ... in California. The study was published this week in the ... the study is that our unique approach is one that ...
Cached Biology News:Will a genetic mutation cause trouble? Ask Spliceman 21 year after Fukushima 21 year after Fukushima 3New study will help protect vulnerable birds from impacts of climate change 2
... Immunogen: Synthetic phosphopeptide corresponding to ... Ser603 residue of rat Synapsin ... synapsin I when phosphorylated at ... Rat (positive control: rat brain ...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
karyopherin alpha2 (2G7)...
... PowerEase 500 Power Supply is ... It offers extensive programming capabilities ... custom methods for you to ... The simple intuitive PowerEase interface ...
Biology Products: